MEIP Company Profile and Key Details
NASDAQ : MEIP
MEI Pharma
$3.07
0.29+10.43%
At Close 4:00 PMNot Actively Trading
66.45
BESG ScoreESG Rating
Price Chart
Stock Price Today
MEI Pharma, Inc. (MEIP) stock surged +10.43%, trading at $3.07 on NASDAQ, up from the previous close of $2.78. The stock opened at $2.89, fluctuating between $2.85 and $3.25 in the recent session.
Stock Snapshot
2.78
Prev. Close
20.45M
Market Cap
2.85
Day Low
-1.2441339287885298
P/E Ratio
-2.46758
EPS (TTM)
-7.95
Cash Flow per Share
2.89
Open
6.66M
Number of Shares
3.25
Day High
85.78%
Free Float in %
8.93
Book Value
3.97M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2025 | 2.67 | 2.83 | 2.64 | 2.71 | 1.11M |
| Sep 15, 2025 | 3.00 | 3.03 | 2.73 | 2.91 | 1.21M |
| Sep 11, 2025 | 2.98 | 3.23 | 2.98 | 3.17 | 1.12M |
| Sep 10, 2025 | 2.89 | 3.25 | 2.85 | 3.07 | 3.97M |
| Sep 09, 2025 | 2.95 | 3.05 | 2.76 | 2.78 | 5.65M |
| Sep 08, 2025 | 3.20 | 3.40 | 2.92 | 3.00 | 6.23M |
| Sep 05, 2025 | 4.34 | 4.45 | 4.08 | 4.23 | 333.49K |
| Sep 04, 2025 | 4.60 | 4.73 | 3.85 | 4.27 | 743.53K |
| Sep 03, 2025 | 4.81 | 4.85 | 4.52 | 4.53 | 360.07K |
| Sep 02, 2025 | 4.75 | 5.15 | 4.75 | 4.85 | 297.3K |
| Aug 29, 2025 | 5.18 | 5.27 | 4.86 | 4.86 | 283.12K |
| Aug 28, 2025 | 5.28 | 5.47 | 5.15 | 5.20 | 320.2K |
| Aug 27, 2025 | 5.29 | 5.50 | 5.15 | 5.16 | 548.73K |
| Aug 26, 2025 | 4.99 | 5.29 | 4.91 | 5.28 | 320.41K |
| Aug 25, 2025 | 4.87 | 5.20 | 4.87 | 5.00 | 283.85K |
| Aug 22, 2025 | 4.65 | 5.00 | 4.58 | 4.97 | 508.7K |
| Aug 21, 2025 | 4.60 | 4.70 | 4.60 | 4.62 | 236.72K |
| Aug 20, 2025 | 4.70 | 4.70 | 4.45 | 4.59 | 382.48K |
| Aug 19, 2025 | 4.85 | 4.85 | 4.60 | 4.68 | 463.1K |
| Aug 18, 2025 | 4.88 | 5.04 | 4.74 | 4.88 | 372.85K |
Contact Details
About Company
MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies. Additionally, Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is undergoing Phase Ib clinical trials for acute myeloid leukemia and other B-cell malignancies. The company is also advancing ME-344, a mitochondrial inhibitor that targets the oxidative phosphorylation complex, through Phase I development for HER2-negative breast cancer. Completing its portfolio is Pracinostat, an orally administered histone deacetylase inhibitor, which is being evaluated in a Phase II clinical trial for myelodysplastic syndrome. MEI Pharma has forged strategic collaborations, including comprehensive license, development, and commercialization agreements with Kyowa Kirin Company and Helsinn Healthcare SA (the latter also encompassing manufacturing). It further holds a clinical collaboration with BeiGene, Ltd. and a licensing agreement with Presage Biosciences, Inc. Founded in 2000 as Marshall Edwards, Inc., the company rebranded to MEI Pharma, Inc. in July 2012 and maintains its corporate headquarters in San Diego, California.
Company Information
| Employees | 28 |
| Beta | 0.22 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-1.37-0.16%
argenx SE$876.25REGN-1.43-0.22%
Regeneron Pharmaceuticals, Inc.$663.09UTHR-11.49-2.10%
United Therapeutics Corporation$535.57MDGL-5.7-1.06%
Madrigal Pharmaceuticals, Inc.$531.00VRTX-5.14-1.06%
Vertex Pharmaceuticals Incorporated$480.25KRYS-2.37-0.65%
Krystal Biotech, Inc.$363.44KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX-10.43-3.21%
Praxis Precision Medicines, Inc.$314.56LGND-6.99-2.21%
Ligand Pharmaceuticals Incorporated$309.25ONC5.26001+1.76%
BeOne Medicines AG$303.96Company Overview
MEI Pharma, Inc. (NASDAQ:MEIP) closed at $3.07 USD, gaining $0.29 (10.43%) from the previous close of $2.78. The stock is currently mid-range between its 52-week high and low $1.46 and $9.00. With a market capitalization of about $20.45 million, MEI Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.22). Key stats such as the average daily volume over the past year has been around 1.53 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, MEI Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Justin J. File CPA, the company employs approximately 28 people and listed since December 18, 2003. MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 -32.45%, SMA50 -32.1%, SMA200 4.35%). The stock’s 14-day RSI is 30.71 (weak momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.89% below its high and over 110.27% above its low.
Valuation Metrics
MEI Pharma, Inc. trades at a P/E ratio of -1.53, slightly below the S&P 500 average, with a price-to-sales ratio of 17.1 and a price-to-book ratio of 1.93 suggesting the stock is closer to book value. The P/FCF stands at -1.96, also below market averages.
Dividend & Fair Value
MEI Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.88. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
The latest quarter delivered EPS of -$0.48. The next quarter is forecast at $nan. Next year's EPS is expected at -$234.02. MEI Pharma, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended February 12, 2025, missed forecasts by -78.18%. The prior quarter beat by -29.41%. Over the last six quarters, Apple has recorded several small beats. These include -499.06% in November 09, 2023.
Shareholding & Insider Activity
MEI Pharma, Inc. has 32.37 million shares outstanding. The public float is 6.21 million shares, elevated short interest at 6.98% of float. This equals 2.15 million shares. The short ratio is 0.82 days. Institutional investors hold 8.8% of the float. Insiders own 7.6%. VIVO VENTURES VII, LLC holds 3.16 million shares, GOLD DANIEL P PHD has 361.63 thousand shares and Vivo Ventures V, LLC has 183.77 thousand shares.
Financial & Profitability Overview
On valuation metrics, MEI Pharma trades at a P/E of -1.53, P/S of 17.10 and P/B of 1.93. The current ratio is 11.53 and quick ratio is 11.53. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 2256.22 days.
Quarterly Financial Highlights
The company ended the quarter with $18.01M in cash and short-term investments, a total debt of $0.00, and net debt of - $18.01M. Total assets were $18.29M, with equity of $16.93M. Financials further reflected weakness, with operating cash flow of - $20.84M, free cash flow of - $20.84M, and capital expenditures of $0.00.
Frequently Asked Questions
What is the current MEI Pharma, Inc. (MEIP) stock price?
MEI Pharma, Inc. (NASDAQ: MEIP) stock price is $3.07 in the last trading session. During the trading session, MEIP stock reached the peak price of $3.25 while $2.85 was the lowest point it dropped to. The percentage change in MEIP stock occurred in the recent session was 10.43% while the dollar amount for the price change in MEIP stock was $0.29.
MEIP's industry and sector of operation?
The NASDAQ listed MEIP is part of Biotechnology industry that operates in the broader Healthcare sector. MEI Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of MEIP?
Mr. David M. Urso B.A., Esq., J.D.
Chief Executive Officer, Pres & Director
Dr. Alejandro D. Ricart M.D.
Senior Vice President of Clinical Devel.
Mr. Brian G. Drazba B.A., C.P.A., CPA
Chief Financial Officer & Sec.
Dr. Daniel P. Gold
Pres, Chief Executive Officer & Director
Dr. Richard G. Ghalie
Chief Medical Officer
Mr. David A. Walsey J.D., L.L.M.
Senior Vice President of Corporation Affairs
Mr. Eugene Park
Vice President of Marketing
Dr. Karen E. Potts Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Tina Clark Beamon Esq., J.D.
Chief Compliance Officer
Ms. Anne Frese
Chief People Officer
Ms. Virginia Sankey
Vice President of Fin.
Dr. Eric Deng Ph.D.
Vice President of Technical Operations
Ms. Yomara Gomez-Naiden
Senior Vice President of Quality
Dr. Robert D. Mass
Strategic Advisor
Mr. Justin J. File
Chief Financial Officer & Corporation Sec.
Mr. Brian G. Drazba B.A., CPA, CPA
Chief Financial Officer & Sec.
Chief Executive Officer, Pres & Director
Dr. Alejandro D. Ricart M.D.
Senior Vice President of Clinical Devel.
Mr. Brian G. Drazba B.A., C.P.A., CPA
Chief Financial Officer & Sec.
Dr. Daniel P. Gold
Pres, Chief Executive Officer & Director
Dr. Richard G. Ghalie
Chief Medical Officer
Mr. David A. Walsey J.D., L.L.M.
Senior Vice President of Corporation Affairs
Mr. Eugene Park
Vice President of Marketing
Dr. Karen E. Potts Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Tina Clark Beamon Esq., J.D.
Chief Compliance Officer
Ms. Anne Frese
Chief People Officer
Ms. Virginia Sankey
Vice President of Fin.
Dr. Eric Deng Ph.D.
Vice President of Technical Operations
Ms. Yomara Gomez-Naiden
Senior Vice President of Quality
Dr. Robert D. Mass
Strategic Advisor
Mr. Justin J. File
Chief Financial Officer & Corporation Sec.
Mr. Brian G. Drazba B.A., CPA, CPA
Chief Financial Officer & Sec.
How MEIP did perform over past 52-week?
MEIP's closing price is 110.27% higher than its 52-week low of $1.46 where as its distance from 52-week high of $9.00 is -65.89%.
How many employees does MEIP have?
Number of MEIP employees currently stands at 28.
Link for MEIP official website?
Official Website of MEIP is: https://www.meipharma.com
How do I contact MEIP?
MEIP could be contacted at phone 858 369 7100 and can also be accessed through its website. MEIP operates from 11455 El Camino Real, San Diego, CA 92130, United States.
How many shares of MEIP are traded daily?
MEIP stock volume for the day was 3.97M shares. The average number of MEIP shares traded daily for last 3 months was 1.53M.
What is the market cap of MEIP currently?
The market value of MEIP currently stands at $20.45M with its latest stock price at $3.07 and 6.66M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep